TOKYO: Alexion Pharmaceuticals Inc said on Thursday its experimental drug to treat patients with a rare blood disorder met the main goal in a late-stage study, sending its shares up 18 percent in premarket trading. The drug, ALXN1210, was being tested against the company’s flagship drug, Soliris, in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). The company said the drug demonstrated non-inferiority to Soliris on the main goal as well as four of the key secondary goals. Alexion said it expects to file marketing application for the drug in the US, the European Union and Japan in the second half of 2018.—Reuters
The image released on April 18, 2024 shows the toss between Pakistan and New Zealand at the Rawalpindi Cricket...
An undated image of the Pakistan Cricket Board Headquarters building in Lahore. — AFPLAHORE: The Pakistan Cricket...
An undated image of former Indian skipper and star batter Virat Kohli. — AFP/FileMUMBAI: Virat Kohli was left fuming...
West Indies head coach Daren Sammy. — AFP FileST LUCIA: With T20 cricket becoming increasingly more...
Pakistan No2 javelin thrower and Asian bronze medalist Mohammad Yasir Sultan. — AFP/FileLAHORE: Pakistan’s No2...
Tennis star Rafa Nadal. — AFP/File ROME: Rafa Nadal will play in the Laver Cup later this year, organisers said on...
